Skip to Content

Generic Olinvyk Availability

Olinvyk is a brand name of oliceridine, approved by the FDA in the following formulation(s):

OLINVYK (oliceridine - solution;intravenous)

  • Manufacturer: TREVENA
    Approval date: October 30, 2020
    Strength(s): 1MG/ML (1MG/ML) [RLD], 2MG/2ML (1MG/ML) [RLD], 30MG/30ML (1MG/ML) [RLD]

Has a generic version of Olinvyk been approved?

No. There is currently no therapeutically equivalent version of Olinvyk available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Olinvyk. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Opioid receptor ligands and methods of using and making same
    Patent 8,835,488
    Issued: September 16, 2014
    Assignee(s): Trevena, Inc.

    This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.

    Patent expiration dates:

    • March 23, 2032
      ✓ 
      Patent use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Opioid receptor ligands and methods of using and making same
    Patent 9,309,234
    Issued: April 12, 2016
    Assignee(s): Trevena, Inc.

    This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.

    Patent expiration dates:

    • March 23, 2032
      ✓ 
      Patent use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Opioid receptor ligands and methods of using and making same
    Patent 9,642,842
    Issued: May 9, 2017
    Assignee(s): Trevana, Inc.

    This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.

    Patent expiration dates:

    • March 23, 2032
      ✓ 
      Patent use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
      ✓ 
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about Olinvyk (oliceridine)

Professional resources

Related treatment guides

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.